- About 20% of users reported experiencing negative side effects when microdosing psychedelics, primarily of a psychological nature.
- Performance enhancement is the main motive for microdosing among users, although many participants stopped because they found it ineffective.
- The majority of respondents microdosed LSD and psilocybin without a clear understanding of the actual doses they were consuming.
Introduction to Microdosing
Microdosing refers to the practice of administering low doses of psychedelic substances like LSD and psilocybin mushrooms to enhance cognitive functions. This approach has gained traction, especially in workplace environments, where many users aim to boost productivity and creativity. Despite extensive media coverage portraying microdosing positively, scientific research documenting its effects—both beneficial and adverse—remains sparse, particularly regarding its use in professional settings.
Survey Methodology
The researchers conducted an online survey targeting psychedelic users from March to July 2018. Participants were required to consent and be at least 18 years old, with prior microdosing experience. In total, 1,116 respondents participated, with data collected on personal demographics, motivations for microdosing, experiences with negative effects, and substance use history.
Findings on Motivation and Use Patterns
Motivations for microdosing were categorized into five primary groups: performance enhancement, symptom relief, mood enhancement, curiosity, and other reasons. Approximately half of the respondents reported microdosing specifically to aid their work activities. The researchers also noted that despite a significant number of users engaging in microdosing multiple times weekly, many did so without a structured plan, and many lacked clarity surrounding the precise dosages consumed.
Side Effects and Discontinuation Reasons
Out of the surveyed microdosers, around 20% noted adverse psychological or physical effects. Although these negative reactions were often transient—subsiding shortly after use—participants reported that their primary reason for ceasing microdosing was its perceived ineffectiveness rather than the adverse effects experienced. The interplay between expectations cultivated by anecdotal media reports and actual experiences could contribute to this perspective.
Conclusion and Future Directions
The researchers highlighted a need for further investigations into microdosing, particularly placebo-controlled studies, to clarify its efficacy for performance enhancement and to catalog potential long-term effects. The findings suggest that while many users pursue microdosing for positive outcomes, a substantial portion of them experiences some negative effects, underlining the complexity of its use. Solutions addressing both the psychological and physiological ramifications of microdosing merit additional academic attention. By understanding user experiences, better guidelines and insights on microdosing practices can be developed in future studies.
Read the full paper summary on Blossom.
